Bautista-León RC, Carrillo-Esper R

Language: Spanish
References: 11
Page: 183-186
PDF size: 218.54 Kb.

ABSTRACT

The diffuse alveolar hemorrhage (HAD) is a clinical syndrome usually manifests with hemoptysis, anemia, hypoxemia, and new alveolar infiltrates on chest radiograph. Currently, the pathogenesis of HAD is not entirely elucidated and is not equal in all the diseases grouped under this classification. Some is due to the production of antibodies against the glomerular capillary and alveolar membrane, as in Goodpasture syndrome. The diagnostic approach can be complicated, because the clinical findings are usually not constant, often missing one or more of the components. ADH is a potentially fatal syndrome characterized by a lack of specific treatment and a high mortality in patients requiring mechanical ventilation.

REFERENCES

1. Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rehumatol 2001; 13(1): 12-7.

2. Green RJ, Ross SJ, Kraft SA, Duncan SR, Berry GJ, Raffin TA. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Clin Chest Med 1996; 110(5): 1305-16.

3. O’Riordan A, Keogh JA, Watson A. Pulmonary renal syndrome due to anti-GBM and IgM C-ANCA disease requiring the use on novel therapeutic agents. Ren Fail 2005; 27(6): 791-4.

4. Travis WD. Pathology of pulmonary vasculitis. Semin Respir Crit Care 2004; 25(5): 475-82.

5. Castro MS, Villagómez AJ, Hernández SS. Hemorragia alveolar difusa en pacientes críticos: casos clínicos y revisión de la literatura. Med Int Mex 2007; 23: 159-71.

6. Cohen S. Diffuse pulmonary hemorrhage: evolutionary flaw of consequence of evolutionary progress? Am J Med Sci 2002; 323(3): 130-9.

7. Estella A, Jareño A, Pere-Bello LF. Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories. Case J 2008; I: 150.

8. Haponik EF, Fein A, Chin R. Managing life-threatening hemoptysis: has anything really changed? Chest 2000; 118: 1431-5.

9. Macdonald JA, Fraser JF, Foot CL, Khoa T. Successful use of recombinant factor VII in massive hemoptysis due to communityacquired pneumonia. Chest 2006; 130: 577-9.

10. Carrillo ER, Elizaondo AS, Sánchez ZM, Carrillo CR. Hemorragia alveolar secundaria a lupus eritematoso generalizado, tratada con factor VI recombinante activado. Informe de un caso y revisión de la literatura. Gac Med Mex 2007; 143(1).

11. Heslet L, Nielsen JD, Levi M, Sengelov H, Johansson P. Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage. Critical Care 2006; 10: R177.